COMPARISON OF SAFETY AND EFFICACY BETWEEN HYDRUS AND ISTENT COMBINED WITH PHACOEMULSIFICATION IN OPEN ANGLE GLAUCOMA SUBJECTS: 24 - MONTH FOLLOW-UP

J. Jabłońska, K. Lewczuk, M. Rękas
Ophthalmology, Military Institute of Medicine, Poland

Purpose: To compare the safety and efficacy of the minimally-invasive ab-interno implants in reducing IOP in open angle glaucoma patients. Methods: A prospective, comparative, uncontrolled, interventional case series. Study comprised 65 patients with cataract and open angle glaucoma: 35 (53.8%) eyes in the iStent group and 30 (46.2%) in the Hydrus group. The mean observation time was 23.06 months in the iStent and 25.09 months in the Hydrus group. Efficacy and safety data included: best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of antiglaucoma medications, visual field, number and type of complications. Results: After 24 months follow-up, the average IOP in the iStent group decreased from 16.06 mmHG to 15.88 mmHg (25% reduction) and from 16.33 mmHg to 16.23 mmHg (22% reduction) in the Hydrus group. At 24 months anti-glaucomatous medications were reduced by 71.67% in the iStent group and by 79.55% in the Hydrus group. No major adverse events were reported. Conclusions: Both minimally-invasive procedure combined with cataract surgery have comparable efficacy and similar approach for controlling IOP and reducing antiglaucoma medications.